A clinical trial of two experimental Ebola vaccines is expected to start in Liberia in the next couple of weeks, the NIH said.» Read More
Stocks closed lower, led by financials, after brokers downgraded several big names in the sector, including American Express.
It's a new month. Time to clean out the inbox. Regarding my post earlier this week about Sen. Chuck Grassley's office breaking the "Nature" embargo on the leak of the GlaxoSmithKline Avandia study, I heard from the "Nature" article reporter.
Stocks closed with a big rally, led by beaten-down financial shares, but still ended one of the worst Januarys in years.
A stock rally fueled by the Fed's latest interest rate cut lost momentum in the final hour after CNBC reported that two big bond insurers could be downgraded as early as today.
European pharmaceutical Roche reported a better-than-expected 25 percent increase in fourth-quarter net profit Wednesday on strong sales of its cancer drugs, despite lower sales of its key influenza drug Tamiflu.
Dow component Merck beat the Street with fourth quarter results on earnings per share (revenue was a sliver below the analyst consensus) and reaffirmed its earnings guidance for this year. Maybe the beaten-down stock is falling victim to another pre-Fed interest rate decision market downdraft...
Merck on Wednesday reported a fourth-quarter loss due to charges from a costly settlement related to its withdrawn Vioxx arthritis drug, but results soundly beat Wall Street forecastsand lifted its shares 2 percent.
Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!
Big Pharma's fortunes rise and fall on the ability to sell hope. Is there any hope for the stocks that trade on hope?
Recession. Bear market. Credit crunch. Is it better to stay out of the stock market or use the recent selloff as a buying opportunity?
In what I would describe as a pretty extraordinary filing with the Securities and Exchange Commission, Schering-Plough is putting in black and white the date and time that senior level executives were informed about the results of the controversial ENHANCE study of the cholesterol drug Vytorin.
I listened in to the hour-long Food and Drug Administration conference call with reporters regarding Vytorin, and I wanted to pass along a few highlights...
Merck and Schering-Plough are being sold off in a classic case of headline overreaction, Cramer says. Don't fall for it.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
ImpactRx--which follows prescription writing for the industry, investors and analysts--is out with a press release this afternoon assessing the damage to Merck and Schering-Plough's cholesterol franchise of Vytorin and Zetia.
The show was over, but Cramer kept going. Don't miss his in-depth answers to audience questions about Merck, Target and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
As I write this at the start of the second hour of regular trading, Pfizer is hangin' on to a small gain. It's the only big pharma stock trading higher this morning and for a moment after the opening bell it was the only Dow component in the green. (Merck and Schering-Plough, still reeling from the Vytorin/Zetia study, are getting pummeled again in the early going--each down more than a buck.)
Pfizer Wednesday reported a higher-than-expected fourth-quarter profit, helped by lower taxes, a weak dollar and growing demand for its drugs for nerve pain, kidney cancer and smoking cession.
This press release and letters to the CEOs of MRK and SGP from the House Energy and Commerce Committee just arrived in my inbox:
I'm blogging today from outside the New York Stock Exchange where I'm trying to round up "man-on-the-(Wall) street" reaction to the markets. In the meantime, back on the beat, for the second day Merck and Schering-Plough have taken out two-page ads in major newspapers defending their cholesterol drugs Zetia and Vytorin whose efficacy is under attack.
Wall Street ended a painful week with skittish investors drawing little comfort from President Bush's stimulus plan. What's the word on the Street?